Up a level |
Zelniker, Thomas A, Wiviott, Stephen D, Raz, Itamar, Im, KyungAh, Goodrich, Erica L, Furtado, Remo HM, Bonaca, Marc P, Mosenzon, Ofri, Kato, Eri T, Cahn, Avivit et al (show 5 more authors)
(2019)
Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Co-Transporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials.
Circulation, 139 (17).
pp. 2022-2031.
Kato, Eri T, Silverman, Michael G, Mosenzon, Ofri, Zelniker, Thomas A, Cahn, Avivit, Furtado, Remo HM, Kuder, Julia, Murphy, Sabina A, Bhatt, Deepak L, Leiter, Lawrence A et al (show 13 more authors)
(2019)
Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus.
CIRCULATION, 139 (22).
pp. 2528-2536.
Furtado, Remo HM, Raz, Itamar, Goodrich, Erica L, Murphy, Sabina A, Bhatt, Deepak L, Leiter, Lawrence A, McGuire, Darren K, Wilding, John PH ORCID: 0000-0003-2839-8404, Aylward, Philip, Dalby, Anthony J et al (show 10 more authors)
(2022)
Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial.
CIRCULATION, 145 (21).
pp. 1581-1591.
Zelniker, Thomas A, Wiviott, Stephen D, Raz, Itamar, Im, Kyungah, Goodrich, Erica L, Bonaca, Marc P, Mosenzon, Ofri, Kato, Eri T, Cahn, Avivit, Furtado, Remo HM et al (show 5 more authors)
(2019)
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
LANCET, 393 (10166).
pp. 31-39.